NASDAQ:OBIO Orchestra BioMed Q4 2025 Earnings Report $5.93 -0.29 (-4.66%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$5.94 +0.00 (+0.08%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS$0.26Consensus EPS -$0.38Beat/MissBeat by +$0.64One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$30.92 millionExpected Revenue$0.93 millionBeat/MissBeat by +$29.99 millionYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateThursday, March 12, 2026Conference Call Time7:00AM ETUpcoming EarningsOrchestra BioMed's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Orchestra BioMed Earnings HeadlinesOrchestra BioMed (NASDAQ:OBIO) Stock Price Expected to Rise, B. Riley Financial Analyst SaysSeptember 17, 2026 | americanbankingnews.comOrchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026September 16, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | Paradigm Press (Ad)Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of VivasureSeptember 15, 2026 | finance.yahoo.comOrchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by HaemoneticsSeptember 15, 2026 | globenewswire.comBTIG upgrades Orchestra BioMed Holdings to buy from neutralSeptember 11, 2026 | msn.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) is a clinical-stage healthcare company developing products for the treatment of cardiovascular and other serious medical conditions. The company uses a partnership-oriented business model, working with medical device and healthcare companies to advance novel therapies toward commercialization. Orchestra BioMed’s leading program is BackBeat Cardiac Neuromodulation Therapy, an investigational device-based treatment designed to provide sustained reductions in blood pressure for patients with hypertension. The therapy is being developed in collaboration with Medtronic and combines an implantable pulse generator with proprietary neuromodulation technology. The company is also developing Virtue Sirolimus AngioInfusion™ Balloon technology, an investigational balloon-based system intended to deliver a therapeutic drug to blood vessels during interventional procedures. Orchestra BioMed has collaborated with Terumo Corporation on development of this program, which is aimed at addressing vascular disease and reducing the risk of restenosis. Orchestra BioMed was formed through a business combination with ARYA Sciences Acquisition Corp IV and began trading on the Nasdaq under the symbol OBIO in 2023. David Hochman serves as the company’s chairman and chief executive officer. Its development activities are focused on the United States and international markets through clinical programs and strategic industry partnerships.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
